Hepatic Sugar Metabolism Measured by PET/CT in Patients and Healthy Subjects

NCT ID: NCT01369979

Last Updated: 2012-06-26

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 13 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2011-05-31
• Study Completion Date: 2012-06-30

Brief Summary

The investigators wish to determine the lumped constant (LC), which is a correction factor necessary for converting measurements of hepatic FDG metabolism (measured by PET) to those of regular glucose in patients with cirrhosis and healthy subjects.

Working hypothesis

• LC for FDG in liver tissue is not significantly different from unity in healthy subjects
• LC for FDG in liver disease is significantly different from LC in healthy liver
• Insulin changes the LC for FDG in liver tissue, but not by the same factor in liver disease and healthy subjects.

Detailed Description

The LC for FDG is determined in 8 patients with liver disease and 8 healthy volunteers with and without glucose-clamp on two different days at 3-5 week intervals. The individual order of the two examinations will be randomized. The subjects fast overnight before the examination but are allowed to drink water and take usual medication.

When arriving at the PET centre, venflons are placed in a cubital vein in both arms and an ICG infusion is started in one of them. On the day with the glucose-clamp, an infusion of insulin and glucose is started in the second venflon. Next, an artflon is placed in one radial artery and a lever vein catheteter is placed via an introducer catheter in the left femoral vein under sterile conditions and local anesthetic (Lidocaine). The position of the liver vein catheter is checked with fluoroscopy.

On each experimental day, a bolus of 200 MBq FDG + 25 μCi [3H] glucose (diluted with saline up to 10 ml) is given intravenously at the start of a 60-min PET scan of the liver. Blood samples from a peripheral artery and a liver vein are collected for determination of blood concentrations of FDG and [3H]glucose at appropriate intervals.

In the experiment with glucose-clamp, an intravenous infusion of insulin (0.6 mU/kg/min) is given and blood glucose is measured every 10 min and kept constant at around 5 mM by infusing 20% glucose (infusion rate adjusted according to blood glucose).

During each study, the hepatic blood flow rate is measured by giving an intravenous infusion of indocyanine green (ICG) and collecting arterial and liver vein blood samples (Fick's principle).

Blood samples are analyzed for concentrations of FDG (gammacounter), [3H]glucose (liquid-scintillation counter), glucose (enzymatic assay) and ICG (spectrophotometric).

When the experiment is finished, all infusions are terminated and the liver vein catheter is removed and hemostasis ensured by manual compression (10 minutes) and bed rest for 30 minutes before the subject is allowed to stand. The artflon is then removed and hemostasis ensured by manual compression (10 minutes). Finally, the venflons are removed.

Conditions

Liver Cirrhosis

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Patients with chronic liver disease

Inclusion criteria

• Age between 40 and 70 years
• BMI between 20 and 26

Exclusion Criteria

• Diabetes mellitus
• Glucose intolerance
• Medical treatment of portal hypertension
• People who have undergone surgery for obesity
• Pregnancy

Liver vein catheter

Intervention Type: PROCEDURE

Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.

Healthy subjects

Inclusion criteria

• Age between 40 and 70 years
• BMI between 20 and 26

Exclusion Criteria

• Diabetes mellitus
• Glucose intolerance
• Medical treatment of portal hypertension
• People who have undergone surgery for obesity
• Pregnancy

Liver vein catheter

Intervention Type: PROCEDURE

Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.

Interventions

Liver vein catheter

Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.

Intervention Type: PROCEDURE

Other Intervention Names

Cook, Torcon NB Advantage Catheter

Eligibility Criteria

Inclusion Criteria

• Age between 40 and 70 years
• BMI between 20 and 26

Exclusion Criteria

• Diabetes mellitus
• Glucose intolerance
• Medical treatment of portal hypertension
• People who have underwent surgery for obesity
• Pregnancy

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Aarhus

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Sørensen, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Aarhus University Hospital, PET-centre

Locations

Aarhus University Hospital, PET-centre

Aarhus C, , Denmark

Countries

Denmark

Other Identifiers

20100284

Identifier Type: -

Identifier Source: org_study_id